Epilepsijos gydymas lamotriginu: atviras klinikinis tyrimas, kurio metu lyginamas rezistentiškos epilepsijos gydymo veiksmingumas ir saugumas, skiriant lamotriginą kartu su karbamazepinu arba valproatu, o vėliau taikant lamotrigino monoterapiją ; Lamotrigine in treatment of epilepsy: an open clinical study evaluating lamotrigine efficacy and safety in concomitant administration with carbamazepine or valproate and consecutive monotherapy

Lamotrigine (LTG) is a novel antiepileptic drug that inhibits release of glutamate and produces voltagedependent block of action potentials and stabilizes neuron membrane. The primary objective of the study was to evaluate efficacy and safety of lamotrigine add-on therapy with carbamazepine (CBZ) or valproate (VPA) and consecutive monotherapy in adult patients with epilepsy whose seizures were not controlled by CBZ or VPA. The measure of efficacy was the number of patients who experienced at least 50% reduction in seizure frequency. Be sides, patients every day assessed their well-being. Of 65 patients recruited in the study, 41 (63%) completed the study. More than 50% of patients during lamotrigine monotherapy experienced from 50% to 75% reduction in seizures and 34% of patients were seizures free. Total frequency of seizures (type I and II) decreased in average 67% in LTG maintenance period (5-12 weeks) comparing to CBZ or VPA monotherapy period (8 weeks before administration of LTG) (95% confidence interval is 56.9-77%). II type seizures were most decreased among all types of seizures (79.2%). Total frequency of seizures (type I and II) decreased in average 75.8% in LTG monotherapy period (21-28 weeks) comparing to CBZ or VPA monotherapy period (8 weeks before administration of LTG) (95% confidence interval is 68.9-82.7%). II type seizures were most decreased among all seizures (83.5%). The well-being of all patients were improved by 10%. LTG was generally well tolerated in add-on therapy with CBZ or VPA. In LTG monotherapy tolerance has led to improvement. 74 adverse events were reported in 30 out of 65 patients (46%). The most common adverse events were headache (28 patients), asthenia (4 patients), fever (4 patients) and dizziness (3 patients). [.].